We have reviewed the literature from the 195CS to the present on the effects of neuroleptics on perceptual and neuropsychological function in chronic schizophrenic patients. In contrast to previous reviews, we have delineated the acute and chronic effects of neuroleptics on individual cognitive and motor tasks by drug, dose, and length of administration. lb date, studies have shown that acute administration of neuroleptics impairs performance on some, but not all, tasks requiring vigilance and attention, and on some tasks requiring motor behavior. Chronic administration of neuroleptics, however, improves performance on some tasks requiring sustained attention and visuomotor problemsolving skills depending on dose and length of administration. Moreover, there is consistent evidence to suggest that chronic administration of neuroleptics in this patient population does not impair neuropsychological function independent of motor function. These findings have direct implications regarding the risk/benefit ratio and legal ramifications for the use of neuroleptics in chronic schizophrenic patients.
The discovery in the early 195CS that chlorpromazine (CPZ) was efficacious in the treatment of psychotic illness led to a number of efforts to define its effects more precisely. By the late 196Cs, controlled studies had demonstrated the value of CPZ and other neuroleptic compounds in reducing target symptoms such as hallucinations, delusions, and agitation, and their relative ineffectiveness in improving some deficit symptoms (Lasky et al. 1962; National Institute of Mental Health 1964; Goldberg et al. 1965; Klein and Davis 1969; Klein et al. 1980) . At the same time, efforts were begun to characterize the range of effects that the new medications might have on overall cognitive, perceptual, and motor behavior. Unfortunately, in contrast to the well-accepted conclusions about many of the effects of neuroleptic medications on traditional target symptoms of psychosis, effects en cognitive, perceptual, and motor behavior have remained much less clearly defined.
The lack of definition does not imply that the area has been ignored. To the contrary, numerous studies have examined medication-induced cognitive, perceptual, and motor changes in normal and psychiatric populations but have led to seemingly contradictory conclusions unresolved by past efforts at systematic review (Cohen 1955; Heilizer 1962; Baker 1968; Heaton and Crowley 1981; Medalia et al. 1988) . In part, this failure to achieve clarification relates to the inherent problems in the existing data themselves. Major reviews of this literature have emphasized the serious inadequacies of many studies and have specifically discussed such significant shortcomings as poor experimental design, lack of placebo or control groups, nonrandom assignment of patients to groups, inadequate washout periods, use of multiple medications, failure to report dosage or duration of drug administration,
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and study populations of uncertain diagnostic composition (Cohen 1955; Heilizer 1962; Baker 1968; Heaton and Crowley 1981; Medalia et al. 1988) .
A significant aspect of the current absence of clarity in this area, however, has been the methodology of previous efforts to review the literature. Prior reviews, at least within the last two decades, have either been selective in their focus, assessing only part of the current literature, or have made insufficient efforts to subdivide existing data according to the tasks being examined, the populations studied, the drugs and dosages used, and the length of drug administration (Cohen 1955; Heilizer 1962; Baker 1968; Heaton and Crowley 1981) . Although the recent review by Medalia et al. (1988) examines the effects of neuroleptics on several categories of neuropsychological function, it does not organize studies according to drug dose or length of administration, and thus is limited in drawing conclusions about drug-response relationships.
The desirability of bringing order to this Literature has been heightened by recent interest in the possible etiological and prognostic significance of neuropsychological abnormalities in schizophrenia and other psychotic illnesses (Klonoff et al. 1970; Goldstein and Halperin 1977; Heaton and Crowley 1981; Kolb and Whishaw 1983; Bilder et al. 1985; Robertson and Taylor 1985) , which must be differentiated from drug effects. In addition, evaluation of the risk/benefit ratio of neuroleptk drug administration, an issue raised most pointedly by court decisions concerning psychiatric patients' rights to refuse treatment (In the Matter of the Guardianship of Richard Roe III, 1981) , requires an assessment of drug effects on cognitive, perceptual, and motor systems. Finally, longer range benefits of obtaining a dearer picture of drug effects may include the possibility that, as the loci of action of the medications are isolated, we will be increasingly able to identify the neural and neurotransmitter systems involved in initiating or modifying behavior (Joseph et al. 1979 ).
This review is an effort to reorganize and reconceptualize the findings related to the effects of neuroleptic medication on neuropsychological functioning in chronic schizophrenic patients. We comprehensively reviewed literature from the 195CS to the present with attention to differing methodologies of the studies. The effects of neuroleptic drugs are examined in the following areas: (1) vigilance and attention, (2) verbal behaviors, (3) learning and memory, (4) abstract thinking and problem solving, (5) motor dexterity, and (6) visuospatial and visuomotor functions.
Methods
We reviewed the psychiatric and psychological literatures from 1956 through 1988 using the Index Medicus and retrieved all studies that indicated the use of well-known neuropsychological or perceptual tests covering one or more of the six areas identified above. We excluded studies examining medication effects on projective test scores, clinical behavioral rating scales, and measures of thought disorder. The studies included in our review demonstrated the following characteristics: a comparison between neuroleptic-medicated and unmedkated subjects, subjects who were described as chronically schizophrenic or psychotic, specification of the length of drug administration, and the presentation of data or narrative data summaries. Although these criteria would seem to include minimal requirements for the reporting of scientific data, as other authors have noted (Heilizer 1962; Baker 1968; Heaton and Crowley 1981) , this Literature is often deficient in these areas.
A major difficulty in identifying appropriate studies for review was ambiguity in the identification of the subject population. Studies in which subjects were identified only as "mental patients" (Allport et al. 1963) , "all psychiatric admissions" (Rosner et al. 1955; Petrie and LeBeau 1956 ), "mixed psychiatric categories" (Shatin et al. 1956; Winter and Frederickson 1956; Howard et al. 1975) , "chronic patients" (Mason-Browne and Borthwick 1957), or newly admitted patients suffering from an acute psychotic episode (HamiLL and Fontana 1975; Wahba et al. 1981) were not included in this review.
Most articles that were included identified subjects as "chronic schizophrenic" or "chronically psychotic" patients. In 13 of 32 studies (Pbrteus 1957; Abrams 1958; Daston 1959; Heilizer 1959; Kornetsky et al. 1959; Siblio et al. 1959; Wynne and Kornetsky 1960; Clark et al. 1963; Chapman and Knowles 1964; Ray et al. 1964; Latz and Kornetsky 1965; Rappaport et al. 1966; Simon 1967) , patients were reported as having been hospitalized with a diagnosis of schizophrenia for from 6 months to more than 2 years. Of the studies that did not specify a minimum length of hospitalization, six (Gardner et al. 1955; Whitehead and Thune 1958; Orzack et al. 1967; Spiegel and Keith-Spiegel 1967; Pugh 1968; Marder et al. 1984 ) reported VOL 16, NO. 3, 1990 479 averages ranging from 7.5 to 18 years and one (Pearl 1962) reported an average of 2.8 years.
The remaining 12 studies did not specify the chronicity of the diagnosis of schizophrenia (Gilgash 1957; Porteus and Barclay 1957; Castner et al. 1958; Grygier and Waters 1958; Nickols 1958; Tourlentes et al. 1958; Judson and MacCasland 1960; Lloyd and Newbrough 1964; Small et al. 1972; Spohn et al. 1977; Fredericks and Finkel 1978; Killian et al. 1984) . Because of the failure of many of the studies to specify the criteria used for the diagnosis of schizophrenia and the evolution of that diagnosis during the time period in question, the subjects in this review are undoubtedly heterogeneous. This diversity of subject populations is the most important limitation of the conclusions listed below.
Of the 32 studies cited in our tables, 24 described subjects assigned to placebo and drug groups. The remaining studies used crossover designs in which the subjects were their own controls.
Tables 1-6 present our results. We used the following criteria to categorize the data; tasks measuring specific neuropsychological skills and functions, type of antipsychotic drug used (we excluded studies with concurrent use of multiple psychoactive drugs), and whether investigators looked at acute (0-3 days) or chronic (7+ days) drug administration. Separate notations are used for each combination of task, drug, and length of administration even if findings resulting from several combinations of conditions were reported in the same article. Tables 1-6 indicate  the name of the task in the leftmost  column, and table 7 provides a brief description of each task.
1 The designation in the tables of no significant change on CPZ -0, significant improvement on CPZ -+, or significant impairment on CPZ = -is based on the original authors' statistical interpretation of their data, requiring a change that was significant at a p value < 0.05. In our review of these data, we also noted when a trend finding was observed (p > 0.05). Although trends are reported as 0 in the tables, such findings are described in the text when relevant.
Phenothiazine and butyrophenone dosages are expressed as CPZ equivalents, using the equivalency charts published by Shader (1975) or Hollister (1978) . There were no studies that specified the use of thioxanthenes. When a wide range of doses was used in an individual study (e.g., 200-1,800 mg/day), or when the drug used was not specified (making it impossible to calculate the CPZ equivalent), data were recorded in the column labeled "Other." Consequently, the potentially confounding data were moved to another category, but not removed from our review. In summary, tables 1-6 reflect the statistically documented effects of neuroleptics on specific tasks within at least six categories of neuropsychological function. (Kornetsky et al. 1959; Latz and Kornetsky 1965) . While all of these findings were generated by the same laboratory (Kornetsky et al. 1959; Latz and Kornetsky 1965 ) on a relatively small number of patients (n = 20), the studies were well designed and used both drug and placebo conditions. In contrast, no decrements in performance have been observed in studies measuring the acute effects of CPZ on simple reaction time (Wynne and Kornetsky 1960) or tasks other than the CPT involving vigilance to tachistoscopic presentation of stimuli (Kornetsky et al. 1959) . Performance on a dichotic listening task was not affected by acute administration of 50 mg of CPZ in a small number of subjects (n -9) in one study (Rappaport et al. 1966) , but this dose of CPZ may have been too low to produce an effect. The four studies exploring the acute effects of CPZ on tasks of attention and vigilance in chronic schizophrenic patients included a total of fewer than 40 patients.
Results
Effects of Neuroleptics on
As can be seen in table 1, chronic administration of CPZ or carphenazine (4-12 weeks) at varying doses (CPZ > 200 mg/day [Spohn et al. 1977 ] and carphenazine at < 400 mg/day [Orzack et al. 1967 controlled studies of chronic schizophrenic patients. There appeared to be no neuroleptic-induced alterations of performance on the Trail Making Test. Five studies measuring simple reaction time (Heilizer 1959; Siblio et al. 1959; Wynne and Kornetsky 1960; Lloyd and Newbrough 1964; Pugh 1968) showed no significant changes, and one study (Spohn et al. 1977) reported drug-induced improvement in only one of four conditions examined. Pearl (1962) found no neuroleptic-induced changes on either simple or complex reaction time.
Only one study of the effects of neuroleptics on speech perception (Fredericks and Finkel 1978) and one study on the Stroop Test (Killian et al. 1984) have been carried out, and no significant effects were observed in these studies. No consistent significant effects were observed on the patients' performance on tasks including the Critical Flicker Fusion, Digit Span, and DSST. One study which did not meet inclusion criteria for our table, (Braff and Saccuzzo 1982) , used a backward visual masking paradigm with tachistoscopic presentation of stimuli and found enhanced speed of information processing in their patients. A recent study by Strauss et al. (1985) reported that serum neuroleptic level correlated inversely with the degree of distractibility on an extended digit-span task; that is, patients with higher serum neuroleptic levels showed fewer effects of distractibility on this task. These findings appeared task-specific, since correlations were not observed with a task of simple reaction time. The articles that specify exact dosages and length of administration of neuroleptics with the DSST, however, provide convincing evidence that there are no significant positive or negative effects of neuroleptics on schizophrenic performance on this task, while the studies (as seen in table 1 under the column "> 8 weeks-Other") with varying or unspecified dosages for various lengths of time show a mixture of no significant effects and significant improvement. Despite these inconsistencies, it should be noted that there is no evidence for any long-term decrements in performance on the DSST with chronic administration of neuroleptics.
Thus, in summary, the acute effects of CPZ on tasks of vigilance and attention have been well studied in a relatively small number of schizophrenic patients since the 1950's. On the basis of these studies, acute administration of neuroleptics appears to impair performance on some but not all tasks involving sustained attention. Performance decrements occurred on the CPT and the DSST, but not on reaction time or other vigilance tasks (aside from the CPT) using tachistoscopic presentation of stimuli.
In contrast, chronic administration of neuroleptics (> 10 days) appears to improve performance on the CPT, but shows no reproducible improvement or impairment of performance on many other tasks involving attention and vigilance studied to date. Since the studies of chronic administration of neuroleptics have involved a larger number of patients (n = 1,071), we can conclude that despite the many differences in the individual studies, reproducible findings do in fact exist when the studies are compared on a task by task basis and when dose of drug and length of administration are equated. To date, there is no evidence for impaired performance on tasks of attention and vigilance with the chronic administration of neuroleptics in chronic schizophrenic patients.
Effects of Neuroleptics on Verbal
Behaviors. Table 2 shows the effects of neuroleptics on various aspects of verbal behavior. All studies reviewed involved the chronic administration of medication. The tests labeled Vocabulary, Information, Comprehension, and Similarities are subtests of either the WechslerBellevue or the Wechsler Adult Intelligence Scale (WAIS). In only one study (Grygier and Waters 1958) , the vocabulary task was not from a Wechsler test. There were no consistent effects of chronic neuroleptic administration on vocabulary tasks. While two of the studies (Gardner et al. 1955; Spiegel and Keith-Spiegel 1967) show significant improvement after chronic administration of either 400-600 mg/day of CPZ (Gardner et al. 1955) or 50-150 mg/day of carphenazine (Spiegel and KeithSpiegel 1967), these findings were not replicated by others (Abrams 1958; Grygier and Waters 1958; Tourlentes et al. 1958) . A closer examination of these studies (to rule out significant differences in length of hospitalization, age, or other factors) reveals no obvious explanation for the inconsistencies in these findings. To date, there appear to be no reproducible significant alterations in performance on information, verbal fluency, and comprehension tasks (see table 2).
Inconsistent findings were observed in a task involving the ability to deduce similarities between objects, although the majority of studies reported significant improvement.
It is of interest to note that among the various studies that reported significant improvement in performance of the Similarities subtest, 
Similarities
Gilgash ( Flekkoy et al. 1969 Flekkoy et al. , 1975 Flekkoy 1975a Flekkoy , 1975b Astrup 1982) (not in table 1 due to the absence of unmedicated control groups) reported improved performance on the quality of word associations in a group of 47 chronic schizophrenic patients at 10-and 16-year followups of their initial performance. While these findings cannot be attributed solely to drug treatment, the patients showed no evidence of deterioration of function on a word-association task when on neuroleptics for an extended period of time.
It is important to note that these summary statements are based on a relatively small number of studies, especially on tasks involving general information, verbal fluency, and word association. Overall, as can be seen in table 2, there is considerable evidence to date that neuroleptics do not impair performance on any of the verbal tasks reviewed.
Effects of Neuroleptics on Abstract Thinking and Problem Solving.
The effects of neuroleptics on tasks requiring the ability to calculate, abstract, or solve problems are shown in table 3. These tasks are a composite of verbal tasks (Arithmetic, Proverbs, and Similarities) as well as those involving visual objectsorting skills (Category Test and Chapman Conceptual Breadth Test) . Again, all studies used chronic administration of neuroleptics. Within the context of the small number of studies to date, there appear to be no deleterious effects of chronic administration of neuroleptics on the ability to carry out orally presented arithmetic problems and to abstract proverbs. Two studies found no significant effects of chronic neuroleptics on objectsorting tasks requiring abstraction skills (Spohn et al. 1977; Fredericks and Finkel 1978) . However, although one study (Chapman and Knowles 1964) observed no significant change in abstract thinking when measuring underindusive thinking (i.e., excessive narrowing of categories); it is of note that these authors observed a significant reduction in overinclusive thinking on this task. Findings on the effects of chronic neuroleptics on the ability to deduce similarities between objects appeared to be drug specific, and were discussed in the previous section.
Given the clinical importance of the question as to whether or not neuroleptics affect abstract thinking and problem solving, the paucity of literature reviewing the effects of neuroleptics on such tasks is quite surprising. It is clear from the findings in table 3 that to date there is little evidence for a dramatic effect of neuroleptics in the direction of improvement on abstract thinking and problem solving in chronically ill schizophrenic patients. However, one study (Wahba et al. 1981) demonstrates in patients described as "acute schizophrenics" (and therefore not included in table 3) improved performance in the ability to interpret proverbs. Given the importance of the implication of these findings, further exploration of the effects of neuroleptics on tasks involving abstraction and problem solving is essential.
Effects of Neuroleptics on Memory and Learning Tasks.
Relatively few studies have looked at the effects of chronic administration of neuroleptics on learning and memory function in chronic schizophrenic patients. The results of the studies to date are shown in table 4. Daston (1959) reported that CPZ (400 mg/day) enhanced paired associate learning on the Wechsler Memory Scale (WMS) in a group of 26 chronic schizophrenic patients while promazine (400 mg/day) did not. Moreover, when CPZ was increased to 1,400 mg/day, there were no longer significant drug effects. On this task, the patient is required to learn a list of easy and difficult pairs of words (e.g., up-down; cabbagepen) over three presentations of the list. Pearl (1962) , however, did not replicate these findings with CPZ or other phenothiazines. Given the important implications of medicationinduced improvement in tasks involving the ability to learn new information and the widespread use of this test in psychological testing, additional research on this test is needed.
Neuroleptics do not appear to alter the schizophrenic patient's ability to retain narrative stories (Logical Memory subtest of the WMS) or carry out tasks involving rote recitation of the alphabet, counting backwards, or counting by 3's from 1 to 40. Neuroleptics in general do not appear to enhance visual memory in these patients as measured by the Visual Designs subtest of the WMS. While Pearl (1962) Pearl ( adverse effects of anticholinergic agents in animals (Deutsch et al. 1966; Squire et al. 1971; Deutsch 1972) and man (Tune et al. 1982) , further studies examining the effects of neuroleptics on memory independent from and in combination with anticholinergic agents are needed before drawing final conclusions about the effects of neuroleptics on learning and memory function. Killian et al. (1984) Story Memory Small et al. (1972) 
Effects of Neuroleptics on Manual
Note.-+ -significant improvement on chlorpromazine (CPZ); 0 -no significant change on CPZ; (+) <• significant improvement on other neuroleptic; (0) -no significant change on other neuroleptic performance on the Finger Tapping Test (Kornetsky et al. 1959; Fredericks and Finkel 1978) , but some authors have reported improvement after 4 or more weeks of CPZ (Tourlentes et al. 1958; Pugh 1968) or perphenazine (Pearl 1962) . However, these results were not replicated by other laboratories (Spiegel and Keith-Spiegel 1967; Small et al. 1972) where no significant effects were observed. Impaired performance after chronic administration of phenothiazines has been observed in only two studies in which the tests administered, the assembly subtest of the Purdue Pegboard (Pearl 1962 ) and the MacQuarrie Test For Mechanical Ability (Spiegel and Keith-Spiegel 1967) , required good control of fine motor movements. These findings are suggestive but have not been replicated by other laboratories, and the effects of tardive dyskinesia have not been addressed in this study.
Effects of Neuroleptics on
Visuospatial/Visuomotor Tasks. Killian et al. 1984) , the Rod and Frame Test (Killian et al. 1984), or Trail Making Tests A and B (Simon 1967; Small et al. 1972; Fredericks and Finkel 1978) . Inconsistent findings on Object Assembly (Abrams 1958; Nickols 1958; Killian et al. 1984) , Picture Completion (Gardner et al. 1955; Abrams 1958; Nickols 1958; Pearl 1962; Killian et al. 1984) , and Porteus Mazes (Gardner et al. 1955; Porteus 1957; Porteus and Barclay 1957; Grygier and Waters 1958) have been reported. One study has reported impaired performance on the MacQuarrie Tracing Test with CPZ, carphenazine, and trifluoperazine (Spiegel and KeithSpiegel 1967) .
In contrast to the above findings, improved performance after chronic administration of CPZ has been observed on two subtests of the Wechsler-Bellevue or the WAIS, Block Design and Picture Arrangement.
Careful review of the studies that examined the effects of chronic administration of CPZ on the ability to replicate three-dimensional block designs revealed that in two of the three studies (Gilgash 1957; Small et al. 1972) showing improved performance on block designs, the authors 
Note.-+ -significant Improveinent on chtorpromazlne (CPZ); --significant Impairment on CPZ; 0 -no significant change on CPZ; (+) -significant improvement on other neuroleptic; (-) -significant Impairment on other neuroteptic; (0) -no significant change on other neuroleptte.
used a maximum of 300 mg/day of CPZ for 3-6 weeks (total number of patients in these studies = 89). A study by Castner et al. (1958) unfortunately did not report the drug doses used. In one study (Abrams 1958 ) that used 400-600 mg/day of CPZ for longer than 8 weeks, no statistically significant improvement on the Block Design subtest was observed after treatment. A recent, well-designed study by Killian et al. (1984) also reported a nonsignificant increase in scores when patients received neuroleptics for 3 weeks, but unfortunately these authors did not specify the dose or dosages of neuroleptics used. It is conceivable that the discrepancy in findings may be related to the dose of medication administered, since studies have only reported scores obtained under time restraints, when manual dexterity and speed would maximally influence performance on the Block Design subtest. On tasks requiring manual or motor dexterity, those studies using high, chronic doses of neuroleptics reported impaired performance (see table 5 ). Studies to clarify these possible dose-related effects on performance on the Block Design subtest are needed. The other task that shows reproducible improvement with chronic administration of neuroleptics is the Picture Arrangement subtest of the Wechsler-Bellevue or WAIS consisting of a series of cartoon pictures that make a story. The task examines the ability to think in a sequential fashion, to synthesize and organize environmental stimuli, and to interpret social situations.
Close inspection of the studies reporting the effects of neuroleptics on Picture Arrangement reveals that administration of CPZ for more than 4 weeks significantly improves performance on the Picture Arrangement subtest (Gilgash 1957; Castner et al. 1958; Small et al. 1972 ) (see table 6 ). While two studies showed no statistically significant changes 490 SCHIZOPHRENIA BULLETIN (Abrams 1958; Nickols 1958) , the findings in these studies were both in the direction of improved performance. In the Abrams study (1958) , inspection of the data reveals that the improvement in performance after CPZ (although not statistically significant) in the experimental group was greater than the improvement in the placebo group. Nickols (1958) commented that the experimental subjects tended to improve substantially more than controls on the Picture Arrangement subtest. The dose of CPZ may again have affected the results, since Nickols' (1958) patients received < 400 mg/day of CPZ and showed "substantial" improvement, while Abrams (1958) reported no significant improvement (but no impairment) on 400-600 mg/day of CPZ.
Clearly, then, five out of five studies saw nominal to significant improvement in patients' ability to arrange pictures to tell stories after chronic administration of CPZ. Greater doses of CPZ (400 mg/day) may reduce the magnitude of these changes by altering manual dexterity (see table 5 ). It would be valuable to explore this clinically relevant finding carefully, and to separate the social interpretation, sequencing, and organizational components of the task from the motor components.
In summary, despite the large number of studies that have explored the effects of chronic administration of neuroleptics on visuospatial and visuomotor functioning, there is no evidence of impairment on most tasks. In contrast, improved performance was observed in two complex tasks (Picture Arrangement and Block Design) which require visuospatial problem-solving skills.
Discussion
Although previous reviews of the effects of neuroleptics on cognitive and perceptual function have noted the difficulties inherent in the literature and the inconsistencies of findings from different laboratories (Heilizer 1962; Baker 1968; Heaton and Crowley 1981; Medalia et al. 1988) , our review has attempted to control for the most important variables by sorting published findings as a function of cognitive task, specific drug, drug dose, and length of drug administration. In this way, we hoped to maximize the opportunity of observing findings that were reproducible across various laboratories, and despite the various flaws in individual studies, to reveal "robust" pharmacological effects. Our original plan to use a metaanalysis of the data (Glass et al. 1981) , which allows the statistical pooling of data from many studies, was abandoned when we found that many authors of the articles we reviewed specified neither the subtype of schizophrenic patients studied nor the diagnostic criteria used for the selection of the patients. In addition, statistical data presented in the article were often insufficient for such analyses. Even in the absence of a meta-analysis, however, we observed reproducible findings (both positive and negative) across various laboratories.
To date, experimental studies have shown that acute administration of CPZ in chronic schizophrenic patients impairs performance on some, but not all, tasks requiring sustained vigilance and attention (i.e., the CPT and DSST tasks; see table 1). In the studies that explored acute neuroleptic effects on motor behavior, dose-related effects and impaired performance were observed on some tasks (i.e., the Finger Tapping Test and the Pursuit Rotor Test; see table 5). Since these effects are time limited, however (i.e., they are not found in studies of chronic administration), and since neuroleptics are usually administered over long time periods to chronic schizophrenic patients, these data may have relatively little clinical relevance. No studies meeting our inclusion criteria have examined acute effects of neuroleptics on abstract thinking and problem solving or memory and learning, and only a small number of studies have been performed on verbal behavior and visuospanal/visuomotor tasks.
The effects of chronic administration of neuroleptics on perceptual and neuropsychological tasks vary depending on the task studied (see tables 1-6), with most tasks showing no effects of the drugs on task behavior. Impaired performance after chronic administration of neuroleptics was observed in two of several tasks requiring fine motor dexterity (see table 5 ). These studies have not yet been replicated by other laboratories. In contrast, improved performance after chronic administration of neuroleptics has been observed with the CPT (table  1) , as has been noted in a previous review (Heaton and Crowley 1981) . In our review of the literature, we also saw evidence for improved performance on the Block Design and Picture Arrangement subtests of the Wechsler-Bellevue or WAIS, which may represent true pharmacological effects of CPZ that were noted but not previously emphasized by other reviewers (Baker 1968) . Since these effects may also be dose related, future studies will be needed to explore further these clinically relevant findings. The subject is asked to answer orally presented arithmetic problems, which range in difficulty from simple to complex.
The subject copies a set of 9 designs, which vary in complexity.
The subject is shown a series of pictures of designs for 5 or 10 sec and is asked to draw them after delays of 0 or 15 sec.
The subject must arrange red and white blocks to correspond to a printed design. This task is timed and the subject receives bonus points for rapid responses.
Stimulus figures consisting of 208 Items divided into 7 sets are shown to the subject. The first 6 sets are organized according to 6 principles. The 7th set consists of previously shown items. The subject presses a key to indicate the principle used in each item.
The subject is asked to sort sets of 30 cards into categories which vary in level of specificity (e.g., fruit, things to eat).
The subject is asked to answer a series of orally presented questions or interpret proverbs requiring the use of common sense, judgment, and social knowledge.
The subject is seated in front of a drum or tachistoscope on which letters and letter combinations appear. The subject receives credit for a response if he presses a key within a specified time of seeing a designated stimuli.
The subject is shown a rotating wheel with sections of different colors and is asked to determine the point at which the colors fuse together without flickering.
The subject listens through dual-track headphones as 2 different strings of numbers are presented simultaneously, one to each ear, and is asked to recall all the numbers presented.
The subject is asked to repeat 3-9 orally presented digits directly after presentation. Then, the subject is asked to repeat strings of 2-8 digits in reverse order.
The subject refers to a row of 9 boxes, each including a letter paired with a corresponding symbol. The subject is then given 90 sec to write the corresponding symbol under each of the numbers presented.
The subject is asked to tap with alternate index fingers for periods of 10 sec on a device that records the number of taps.
The subject identifies a hidden figure by marking the outline of a simple figure embedded in a more complex one.
The subject is asked to answer questions that reflect early academic information and general fund of knowledge.
Two paragraphs are read to the subject. After each paragraph, the subject is asked to repeat the content of that paragraph.
The subject must draw a continuous line through irregularly placed gaps in vertical lines without touching the lines.
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The subject must draw a line from the entrance to the exit of a maze without entering any blind alleys or crossing any lines.
The subject sits in front of a revolving electric drum with words on it. As the drum turns, the subject is asked to read and remember the words that appear in a slit.
The subject is shown each of 15 geometric designs of varying degrees of complexity for 5 sec and is asked to draw each design after seeing it.
The subject is timed while performing the following tasks: reciting the alphabet, counting backwards from 20 to 1, and counting by 3's from 1 to 40.
The subject is asked to assemble each of 4 cardboard puzzles.
The subject is asked to listen to a list of 10 pairs of related or unrelated words, and when presented with the initial word in each pair, is asked to supply the other. The subject is administered 3 trials of the list, and the number of correct and incorrect responses is recorded.
The subject is asked to arrange a set of cartoon pictures to make a coherent story.
The subject must tell what important part is missing from each of 21 pictures.
The subject is administered a written test to interpret 12 proverbs.
The subject must assemble a pin, 2 washers, and a sleeve into a patterned unit.
The subject must place pegs in holes within 30 sec with the left hand, right hand, and then both hands simultaneously.
The subject is required to use a hand stylus to keep contact with a target on a revolving circular disk.
The subject is timed while responding to a stimulus by pressing a button key.
The subject must discriminate between like and unlike pairs of musical beats.
The subject is given 8 trials to adjust a rod to a vertical position in a frame of varying orientations.
Same as the Digit Symbol Substitution Test but untimed.
The subject is presented 12 pairs of words and asked to tell how each pair is alike.
The subject is asked to adjust a circle of lights to be equal in size to a handheld disk.
The subject is asked to tell the number of dots that are flashed on a screen by tachistoscopic presentation. The subject is shown a geometric design on a stimulus card and is asked to choose the correct orientation of that design from 4 multiple choice options.
The subject is presented with nonsense syllables beginning and ending with different consonants but based on the vowel sound "ee"; the subject then indicates the sounds that he or she heard on a multiple choice form.
The subject is timed as he or she reads a list of words or identifies colors presented according to varying instructions and degrees of distraction.
For 10 sec the subject taps as fast as possible with a stylus on a metal plate.
The subject sits In front of an apparatus with a shutter that opens for brief intervals to expose stimuli in the form of slides or pictures. The subject follows a command related to the exposed stimulus image (e.g., presses a key).
The subject is blindfolded and asked to place blocks and shapes in a formboard with preferred, nonpreferred, and both hands. After removing the blindfold, the subject attempts to draw the formboard from memory.
In Part A of this test, the subject draws lines to connect consecutive numbered circles. In Part B, the subject connects numbers and letters presented alternately (e.g., 1-A, 2-B). The test is timed and the number of errors is noted.
The subject is given a limited amount of time to say as many words as possible that meet a specification (e.g., beginning with a certain letter).
100 familiar English nouns and adjectives presented orally to the subject who is requested to respond to each stimulus word with a 1-word association.
Nora-WAIS = Wechsler Adult Intelligence Scale; WMS -Wechsler Memory Subtest.
'Specific references for the tests used in these studies can be found In the references of the research articles found In tables 1-6.
In light of our review, there is consistent evidence in the literature to suggest that chronic administration of neuroleptics does not impair cognitive or neuropsychological function independent of motor function. Some tasks, but not all, that require fine motor movements may be compromised by chronic administration of neuroleptics. These findings are consistent with the known literature on tardive dyskinesia and the Parkinson-like symptoms in patients chronically treated with neuroleptics (Lasky et al. 1962; Goldberg et al. 1965; Klein and Davis 1969; Klein et al. 1980) .
In studies demonstrating improved performance after chronic administration of neuroleptics, it is unclear whether improvement is due to the direct effects of these drugs on neuropsychological function or is secondary to overall improved clinical or behavioral status. For example, the reproducibility in the literature of improved performance on the Block Design and Picture Arrangement subtests necessitates our close reexamination of the meaning of these findings. On the basis of the available literature, we are unable to distinguish whether the improved performance on Block Design and Picture Arrangement subtests results from improved attention, motor speed, and performance on these tasks (as measured by the timed test) or from improvement in conceptual ability on these tasks (as reflected by the subjects' qualitative performance or untimed performance on these tasks). Future studies will be needed to examine these possibilities. It is important to note that while some studies document significant improvement in some areas of neuropsychological function, we cannot assume that these findings mean a return to "normal" function.
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The potential methodological limitations of this review must be considered. First, our exclusion of studies of patients experiencing their first psychotic episode causes the relevance of many of our findings to be limited to more chronic patients. Second, in view of the recent notion of classifying subtypes of schizophrenic patients as neuroleptic responders and nonresponders (Csernansky et al. 1985) , it may be that the limited number of positive medication effects found in this review could be explained by the possibility that the studies selected populations of chronic schizophrenic patients who were essentially "nonresponders." However, the reproducibility of findings of no change, improvement, or impairment across several laboratories on several specific tasks makes this argument less tenable. Third, one could argue that given the heterogeneity of subgroups of schizophrenic patients, the small number of both positive and negative effects simply represents the canceling out of true effects by the different subtypes when they were combined in the experimental group. As Asarnow et al. (1988) have recently noted, it may be that combining patients with intact versus impaired information-processing abilities, for example, may "average out" significant findings such as drug efficacy and treatment response. Spohn et al. (1985) confirmed that high doses of neuroleptics, in contrast to low doses, could differentially impair performance on specific tasks such as reaction time and span of apprehension in chronic schizophrenic patients. However, the reproducibility of findings in tables 1-6 across various laboratories given similar dose ranges and length of administration makes the task-specific findings more difficult to ignore.
Finally, because of the large number of studies reviewed, there is also the possibility that by chance alone on any one or two tasks there would be reproducible studies showing similar findings. The improvements seen on both the Block Design and Picture Arrangement subtests represent changes that are similar to the clinical effects of neuroleptics reported in the literature using behavioral rating scales and observational studies (Lasky et al. 1962; National Institute of Mental Health 1964; Goldberg et al. 1965; Klein and Davis 1969; Klein et al. 1980 )-a point supporting the validity of the findings. Killian et al. (1984) proposed "that psychological studies of schizophrenia be directed to processes and functions that may be clearly implicated in the disorder and that psychopathologists abandon the use of tests and laboratory procedures that are recommended only by their availability and familiarity" (p. 59). These authors were responding to the fact that although studies to date on the effects of neuroleptics on cognitive functions in schizophrenia have been of interest to the experimental psychologist and psychopathologist, they have had limited pragmatic value for the clinician. Some studies exploring the effects of neuroleptics on abstract thinking, problem solving, and memory function have been performed (revealing little or no alteration of such functions), but there have been few complete studies on the effects of neuroleptics using batteries of neuropsychological tests that would be interpretable on a clinical basis (Small et al. 1972; Howard et al. 1975 ) and would permit localization of brain dysfunction.
Implications for Further Research and Conclusions
On the basis of tables 1-6, one can begin to outline the areas appropriate for such investigation. The effects of neuroleptics on such tasks as simple reaction time, digit symbol substitution, and finger tapping have already been studied repeatedly (see table 1). Thus, for further studies in these areas to be worthwhile, research must take a new perspective to study. Few studies have been performed on the effects of neuroleptics on abstract thinking and problem solving, memory and learning, complex motor tasks, and visuospatial and visuomotor functioning.
Our findings also have implications for the design of future studies. They suggest that while low to moderate doses of CPZ may have specific effects, these effects may be diminished or obscured by the opposite effects of these drugs at higher doses. When the results of existing studies are separated by dose and length of administration, there are far fewer inconsistencies in the literature (compare dose-specific columns to "Other" columns in tables 1-6). Researchers will need to control for these variables by comparing drug effects under different conditions of dosage and administration. In view of the differential metabolism of these drugs across individuals, obtaining the patients' neuroleptic blood levels would be desirable. Further; it would be interesting to examine whether schizophrenic patients who improved on neuroleptics showed different patterns of response from those who improved spontaneously on placebo. In addition, it may not be safe for investigators to assume that all neuroleptics have identical effects on all perceptual, cognitive, and motor tasks; particularly in naturalistic studies, appropriate controls may be needed.
As others have noted, rigorous diagnostic assessment of the populations studied is essential to ensure comparability of results. Neuropsychological deficits have been well documented in at least some subtypes of schizophrenic patients as measured by the Halstead Reitan Battery (e.g., Klonoff et al. 1970; DeWblfe et al. 1971; Goldstein and Halperin 1977; Flor-Henry and Yeudall 1979) , the Montreal Neuropsychological Battery (Kolb and Whishaw 1983) , and other assessment procedures (Taylor et al. 1981; Bilder et al. 1985; Robertson and Taylor 1985) . More recent studies have described widespread frontal and temporal lobe deficits in medicated schizophrenic patients using regionally sensitive neuropsychological batteries (Kolb and Whishaw 1983) . Specification of subtypes of schizophrenic patients is essential to a further clarification of medication effects.
There may also be good reason to control for the status of subjects as responders or nonresponders to medication. Since neuroleptics have anticholinergic effects, and given evidence that anticholinergic drugs may affect memory in animals (Deutsch et al. 1966; Squire et al. 1971; Deutsch 1972 ) and man (Tune et al. 1982) , one may need to control for the level of anticholinergic activity or concomitant use of these ubiquitous medications as well.
Since our review of the literature found few effects of neuroleptics on many cognitive tasks, we are faced with two possible conclusions: (1) To date, on the basis of the cognitive tasks reviewed, widespread neuropsychological deficits observed in at least some subtypes of schizophrenic patients are not due to neuroleptics, but to brain dysfunction or pathology (see Seidman 1983); or (2) the tests that were used to measure the effects of neuroleptics on cognitive functions were insensitive to the types of quantitative and qualitative changes that may occur clinically. Subtle changes would more likely be detected using more sophisticated neuropsychological assessment strategies. No studies to date have assessed the effects of neuroleptics on neuropsychological patterns of function and dysfunction, emphasizing both regional and functional alterations in cognition (as illustrated by the Montreal [Kolb and Whishaw 1983] and Boston process techniques [Weintraub and Mesulam 1985; Milberg et al. 1986; Kaplan 1988] for neuropsychological assessment). Until such studies are performed, it may be premature to conclude that chronic administration of neuroleptics has few effects on neuropsychological function.
Our findings have several implications that may illuminate the ethical and legal disputes concerning the administration of neuroleptics to chronic schizophrenic patients. First, there is significant evidence to date that neuroleptics do not impair cognitive abilities; in fact, chronic administration of these medications may improve function for at least some complex cognitive tasks requiring sustained vigilance and attention, problem solving, and ability to organize.
Second, our findings may be relevant to the formation of strategies to assess patients' competence to give informed consent with and without medications. Although this subject is too extensive to address here, our description in this review of patients' improvement on clusters of tests, rather than individual tests of cognitive functioning, suggests that a battery of tests, rather than individual criteria, may provide more valid competency assessments.
On the basis of the available data, the risk of impaired cognitive function appears to be low compared to the benefits of improved clinical status observed in neuroleptic responders. Although the possibility of other side effects (e.g., tardive dyskinesia) must be taken into account in any risk/benefit analysis, the findings on cognitive function show little reason for concern regarding appropriate medication use. Many courts (e.g., In the Matter of the Guardianship of Richard Roe III [1981] ) have been unrealistically extreme in their assessment of the cognitive effects of standard dosage levels of these medications (Gutheil and Appelbaum 1983) . For the group of patients who do not appear to respond clinically to neuroleptics, however, it is unclear whether the small improvements noted on select cognitive tasks outweigh the risks of neuroleptics. This point underscores the need for empirical demonstration of clinical response to neuroleptic treatment in clinical practice.
